PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.25%
Negative revenue growth while Drug Manufacturers - Specialty & Generic median is 1.64%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-11.81%
Negative gross profit growth while Drug Manufacturers - Specialty & Generic median is 0.39%. Seth Klarman would suspect poor product pricing or inefficient production.
-1070.05%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 10.81%. Seth Klarman would check if external or internal factors caused the decline.
-1070.05%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 10.44%. Seth Klarman would check if structural or cyclical issues are at play.
433.16%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 27.00%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
306.74%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 24.93%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
306.74%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 24.93%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
17.10%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
16.43%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
437.30%
OCF growth of 437.30% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest positive difference, which can compound over time.
-403.23%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
197.22%
OCF/share CAGR of 197.22% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
197.22%
OCF/share CAGR of 197.22% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
750.80%
3Y OCF/share growth of 750.80% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
253.30%
Net income/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 39.48% over a decade. Joel Greenblatt might see a standout compounder of earnings.
253.30%
5Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 13.38%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
386.95%
3Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 31.79%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
964.68%
Equity/share CAGR of 964.68% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
964.68%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 1.25%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
2364.73%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 7.37%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.82%
AR shrinking while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-5.96%
Decreasing inventory while Drug Manufacturers - Specialty & Generic is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
48.98%
Asset growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.33%. Joel Greenblatt confirms strong expansions matched by adequate returns on those assets.
28.76%
BV/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median. Joel Greenblatt checks if consistent ROE or undervalued buybacks fuel this advantage.
18.59%
Debt growth of 18.59% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
10.45%
R&D growth of 10.45% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
34.18%
SG&A growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.